• Randomised, double-blind, placebo-controlled trial recruiting 240 participants
• Investigating efficacy of proprietary probiotic strain Lactobacillus plantarum BMB18 in adults with digestive, sleep and mood issues
• Successful trial outcomes to unlock new product development opportunities

Biome Australia Limited (ASX: BIO) has announced that the La Trobe University Human Research Ethics Committee has granted ethics approval for the company's first human clinical trial on its proprietary probiotic strain, Lactobacillus plantarum BMB18 (DSM 35214). The randomised, double-blind, placebo-controlled trial will recruit 240 participants across two active dosage levels and placebo to investigate the efficacy of BMB18 in adults experiencing digestive symptoms, sleep and mood disturbances. The 12-month study will examine the impact of BMB18 on digestive function, mood, sleep and quality of life. BMB18 is wholly owned by Biome and registered with the German culture bank DSMZ, providing the company with protectable intellectual property and future licensing opportunities. Successful clinical validation of BMB18 will support new product development across Biome's Activated Probiotics and Activated Therapeutics ranges, with the potential to address multiple health applications. The trial aligns with Biome's Vision 27 strategic plan, specifically the supply chain development pillar focused on identification, characterisation and commercialisation of proprietary probiotic strains.

Successful clinical outcomes for BMB18 will unlock new product development opportunities across Biome's Activated Probiotics and Activated Therapeutics ranges.